



PERIPARTUM CARDIOMYOPATHY
(PPCM)
presentation by ONADIPE SOLABOMI

A top-down photograph of medical supplies on a solid pink background. A black stethoscope is coiled on the left. A pair of white latex gloves is in the upper right. A green surgical mask and a pair of black-rimmed glasses are in the center. A silver pen and a spiral-bound notebook are at the bottom. The text 'TABLE OF CONTENTS' is overlaid in white, bold, sans-serif font.

TABLE OF CONTENTS

- Case scenario
- Normal cardiovascular changes in pregnancy
- Definition
- Etiology
- Clinical presentation
- Diagnosis
- Management
- Prognosis

CASE SCENERIO

A woman 29 yrs old admitted to ICU through emergency

With complaints of severe dyspnea and fatigue on 2nd puerperal day of her first pregnancy without h/o of any this type of symptoms before and delivery was uneventful. She had no h/o of repeated respiratory tract infection and previous hospital admission.

On examination pt is afebrile, BP-140/80mmHg, pulse-90beat/min, regular, R/R-25/min, O₂ saturation-80% without O₂, JVP-normal, lungs- bilateral basal crepitation, heart- 1st and 2nd heart sound normal, S3 gallop present, oedema- moderate, NT-pro BNP- 864pg/ml


-ECG shows sinus tachycardia,

-Chest ray shows cardiomegaly with increase bilateral congestion,

- A transthoracic echocardiogram done at admission showed an LV ejection fraction of 35% to 40%, with trace aortic and mitral regurgitation.



PHYSIOLOGIC CHANGES IN PREGNANCY: CARDIOVASCULAR



PHYSIOLOGICAL CHANGES IN PREGNANCY

What is peripartum cardiomyopathy?

-PPCM is defined as an idiopathic cardiomyopathy that presents with heart failure secondary to left ventricular (LV) systolic dysfunction toward the end of pregnancy or in the months after delivery, in the absence of any other cause of heart failure.

-This is a diagnosis of exclusion, and the majority are diagnosed postpartum

It is associated with all four of the following:


1. Heart failure within: last month of pregnancy - 5 months postpartum
2. Absence of prior heart disease
3. No determinable cause
4. Strict echocardiographic indication of left ventricular dysfunction:

Ejection fraction <45%

EPIDEMOLOGY



- United States statistics-Reports estimating the incidence of PPCM ranges from 1 case per 1000-4000 live births.
- The prevalence is reported to be 1 case per 6000 live births in Japan
- 1 case per 1000 live births in South Africa,
- 1 case per 350-400 live births in Haiti.
- 1 case per 100 live births in Nigeria
- A high prevalence in Nigeria has been attributed to the tradition of ingesting kanwa (dried lake salt) while lying on heated mud beds twice a day for 40 days postpartum.
- Approximately 75% of cases are diagnosed within the first postpartum month.
- Approximately 50% of cases occur in women older than 30 years.

CENTRAL ILLUSTRATION: Outcomes of Peripartum Cardiomyopathy in Nigeria



Karaye, K.M. et al. J Am Coll Cardiol. 2020;76(20):2352-64.

Etiology/ Risk factors



Symptoms

- Fatigue
- Feeling of heart racing or skipping beats (palpitations)
- Increased nighttime urination (nocturia)
- Shortness of breath with activity and when lying flat
- Swelling of the ankles
- Cough
- Chest pain or tightness



Differential diagnosis

Table 1 Peripartal acute dyspnoea: differential diagnosis of acute peripartum cardiomyopathy

	PPCM	Pre-existing CMP, valve disease or congenital heart disease	Pregnancy-associated myocardial infarction	Pulmonary embolism/ amniotic liquid embolism	Myocarditis
History	Most commonly post-partal onset of dyspnoea	Earlier onset (during second trimester) Sometimes family history	Retrosternal chest pain, abdominal discomfort, nausea	Pleuritic chest pain	Infection
Biomarkers	Elevated natriuretic peptides	Elevated natriuretic peptides	Elevated troponin	Elevated D-dimer, troponin, natriuretic peptides	Elevated troponin Possibly elevated natriuretic peptides
Echocardiography	Left and/or right ventricular dysfunction	Evidence of pre-existing valve disease or congenital defect	Regional hypokinesis/akinesis	RV dysfunction, elevated RV pressure, McConnell's sign	Regional or general hypokinesis
Additional tests	Consider MRI	Consider MRI Consider genetic test	Coronary angiography	CT-scan or V/Q scintigraphy; consider angiography	MRI Consider myocardial biopsy

CMP, cardiomyopathy; MRI, magnetic resonance imaging; PPCM, peripartum cardiomyopathy; RV, right ventricular.

* ANEMIA

* THYROID DISEASE

*

PREEEXISTING CARDIOMYOPATHY OR CHD

* ACCELERATED HTN

* MYOCARDIAL INFARCTION

* ACUTE PULMONARY EMBOLISM


* SEVERE PREECLAMPSIA

MYOCARDITIS

* PREVIOUS VALVULAR DISEASES

Diagnosis

- Complete blood cell count with differential
- Electrolyte levels, including magnesium and calcium, creatinine and Urea
- Levels of cardiac enzymes, including troponin
- Level of B-type natriuretic peptide and/or N-terminal pro-B-type natriuretic protein
- Liver function test
- Level of thyroid-stimulating hormone (TSH)
- Chest radiograph
- Electrocardiogram
- Transthoracic echocardiogram
- Cardiac magnetic resonance imaging and/or endomyocardial biopsy (when/if indicated)



Chest X-ray and ECG findings.

Findings on chest Xray


- Enlarged Cardiac shadow or silhouette , Hyperemic lung field (due to pul. congestion), Bilateral plural effusion

Findings on ECG

Most commonly -Sinus tachycardia and Arrhythmia (e.g atrial fibrillation)


Others -

- LVH with strain pattern
- Low voltage QRS complex with inverted T wave
- Nonspecific ST-T wave changes



ECHO Findings

ECHOCARDIOGRAPHY



Echocardiography findings:

(a and b or c, or all a-c)

a. LVEDD > 2.7 cm/m³

b. M-mode fractional shortening $< 30\%$

c. LVEF $< 45\%$

LVEF: Left Ventricular Ejection Fraction:

LVEDD: Left Ventricular End Diastolic
Dimension

MANAGEMENT.

-Multidisciplinary Approach


The goal of management is to improve the cardiac output.

Management majorly consists of

- Preload reduction -(diuretics- loop diuretics , sodium restriction, fluid restriction)
- Afterload reduction (BBs, ACEIs, ARBs, Mineralocorticoid receptor antagonist)

Note- ACEIs and ARBs are contraindicated peripartum, ACEI can be used during lactation

- Anticoagulation (LMWH, Unfractionated heparin)



PPCM: peripartum cardiomyopathy
RAS: renin-angiotensin-aldosterone system

MANAGEMENT CONTD

Management during Pregnancy

- Regular checkup, blood tests and ECHO
- Avoid ARB/ACE-I
- Avoid Warfarin and DOAC
- Planning for delivery mode and timing with Cardiology and Obstetrician

Management during Delivery

- Stable patients typically deliver vaginally
- Prompt delivery in patients with severe HF.
- A multi-disciplinary team is critical!
- If hemodynamically unstable , then ICU care and possible cesarean section.

Management Post partum

- Cardiology checkup with continuation of medications and regular ECHO
- Breast-feeding- Some studies show no ↓ LV function. Avoid ARBs
- ICD-implantable cardioverter-defibrillator- Possible role for wearable defibrillator as a "bridge to recovery"
- Contraception counseling -Avoid estrogen products early post-partum



ANTICOAGULANT S

PPCM is associated with higher rates of thromboembolism as the Peripartum period is hypercoagulable state.

Indications for Anticoagulant use

- PPCM patients with LVEF less than 35%
- Use of bromocriptine (associated with thromboembolism)
- Given as prophylaxis up to 8 weeks post-partum


Drugs

LMWH and unfractionated heparin used antepartum

Warfarin used post-partum, Rivaroxaban (xarelto) also used

BROMOCRIPTINE AND PPCM

- Lower STAT3 expression and higher serum levels of 16 kDa prolactin are found in women with PPCM compared to controls.
- Administration of bromocriptine to block prolactin reversed PPCM in STAT3 deficient mice.
- Higher rate of LVEF recovery with both long (8 week) and short term bromocriptine could be an addition to heart failure therapy
- Side effects of bromocriptine include inhibition of lactation and thromboembolism.





Prognosis

Good prognosis from other forms of dilated cardiomyopathy

- 50% patients - complete recovery
- 25% patients - persistent symptoms
- 25% patients – develop complication (progressive heart failure, arrhythmia, thromboembolism)

Mortality rate - 3% to 9.6%

Pt with persistent cardiomegaly after six month -mortality rate 85% in 5 yrs.



Thank you